SCHEMBL1036616

SCHEMBL1036616

CCCS(=O)(=O)OCCCOc1ccc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.49
KDM4E B2RXH2 3/20 0.49
MAPK1 P28482 2/20 0.49
GAA P10253 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
DRD3 P35462 1/20 0.45
HRH3 Q9Y5N1 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HDAC1 Q13547 1/20 0.44
PPARG P37231 1/20 0.44
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
AGXT P21549 2/20 0.42
PTPN7 P35236 1/20 0.42
MCL1 Q07820 1/20 0.42
HRAS P01112 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16479165 0.84 AGXT (0.49) TDP1KDM4EMAPK1RAB9ANPC1
SCHEMBL30189577 0.82 KDM4E (0.54) TDP1KDM4EMAPK1GAAL3MBTL1
SCHEMBL3310045 0.82 KDM4E (0.54) TDP1KDM4EMAPK1GAAL3MBTL1
Naphthalene SCHEMBL27740230 0.80 CA1 (0.42) TDP1GAAL3MBTL1ALDH1A1HTT
Naphthalene SCHEMBL27760899 0.80 CA2 (0.39) TDP1MAPK1GAAL3MBTL1ALDH1A1
SCHEMBL470925 0.79 TDP1 (0.68) TDP1KDM4EMAPK1RAB9ANPC1
SCHEMBL29666114 0.79 TDP1 (0.68) TDP1KDM4EMAPK1RAB9ANPC1
SCHEMBL13666949 0.79 KDM4E (0.42) TDP1KDM4EMAPK1RAB9ANPC1
SCHEMBL27881561 0.79 L3MBTL1 (0.59) TDP1MAPK1GAAL3MBTL1RAB9A
SCHEMBL3310123 0.78 MEN1 (0.52) TDP1KDM4EMAPK1GAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2276717-A1 PURIFICATION STRATEGY FOR DIRECT NUCLEOPHILIC PROCEDURES Bayer Schering Pharma Aktiengesellschaft (DE) 2011-01-26 EP disclosed
WO-2009127372-A1 PURIFICATION STRATEGY FOR DIRECT NUCLEOPHILIC PROCEDURES BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-10-22 WO disclosed